Vivos Therapeutics, Inc. cash flow to debt ratio of -113.04% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Vivos Therapeutics, Inc.'s free cash flow has decreased 32.77% from $-13.26M last year to $-17.60M, signaling decreasing performance

Vivos Therapeutics, Inc.'s debt to equity ratio is -10.78, signaling that the company spent its equity and risk bankruptcy.

Vivos Therapeutics, Inc.'s debt to equity ratio is -10.78, signaling that the company spent its equity and risk bankruptcy.

Vivos Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in Vivos Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Vivos Therapeutics, Inc.'s profit margin has decreased (73.26%) in the last year from -74.09% to -128.36%, signaling decreasing performance

Vivos Therapeutics, Inc.'s short-term liabilities of $18.08M exceed its short-term assets of $4.38M, signaling financial risk

Vivos Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Vivos Therapeutics, Inc.'s return on equity of -2.24K%, is lower than 15.00%, indicating bad performance

Vivos Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vivos Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Vivos Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Vivos Therapeutics, Inc. has negative free cash flow, indicating cash burn

Vivos Therapeutics, Inc.'s yearly earnings has decreased 90.64% since last year from $-11.14M to $-21.23M, signaling decreasing performance

Vivos Therapeutics, Inc.'s yearly revenue has increased 16.05% since last year from $15.03M to $17.44M, signaling increasing performance

ROIC -148.61% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Vivos Therapeutics, Inc.'s 3-year revenue CAGR of 2.87% is positive, indicating growing revenue over the past 3 years

Vivos Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Vivos Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Vivos Therapeutics, Inc. has insufficient data to evaluate this check.

Vivos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vivos Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Vivos Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Vivos Therapeutics, Inc. has insufficient data to evaluate this check.

Vivos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vivos Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Vivos Therapeutics, Inc. has a price-to-sales ratio of 0.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue